Newscasting from ESC 2024 – Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration
Newscasting from ESC 2024 – Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration An analysis of the SCORED trial from the European Society of Cardiology (ESC) Congress 2024 highlights the effect of the SGLT1/2 inhibitor sotagliflozin (Inpefa) on heart failure outcomes based on diabetes duration. Results of the analysis, which were presented by Rahul Aggarwal, MD, of […]
ESC 2024 – FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease
ESC 2024 – FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease Use of semaglutide 1.0 mg (Ozempic) offers benefits on cardiovascular outcomes, regardless of baseline chronic kidney disease severity, according to an analysis of the FLOW trial presented at the European Society of Cardiology (ESC) Congress 2024. Presented by Kenneth Mahaffey, MD, professor […]
From ESC 2024: M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation
From ESC 2024: M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation Results of RESHAPE-HF2 suggest use of mitral transcatheter edge-to-edge repair (M-TEER) was more effective than optimal medical therapy alone for reducing cardiovascular event risk among patients with heart failure and moderate to severe mitral regurgitation ineligible for surgery. Presented […]
Reporting from ESC 2024: Single Blood Test Could Predict Cardiovascular, Stroke Risk in Women for Up to 30 Years
Reporting from ESC 2024: Single Blood Test Could Predict Cardiovascular, Stroke Risk in Women for Up to 30 Years A single blood test could predict cardiovascular for women for up to 3 decades, according to new research presented at the European Society of Cardiology (ESC) Congress 2024. The study, which leveraged high-sensitivity CRP (hsCRP), LDL cholesterol, […]
News Coverage from ESC 2024: In Women, History of Cancer Linked to Subclinical Atherosclerosis
News Coverage from ESC 2024: In Women, History of Cancer Linked to Subclinical Atherosclerosis New research presented at the European Society of Cardiology (ESC) Congress 2024 is making the case that clinicians should consider cancer as a risk factor for subclinical atherosclerosis. Presented by Sara Diaz Saravia, MD, of Mount Sinai Morningside, the study, which was a […]
From ESC 2024: Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA
From ESC 2024: Common Pitfalls to Avoid When Interpreting Clinical Trials, with Deepak Bhatt, MD, MPH, MBA Although clinical trial data can prove invaluable and have practice-altering implications, the timeline from data release to adoption into clinical practice can sometimes take years. According to a study conducted in 2011, it takes approximately 17 for scientific […]
Newly reported from ESC 2024: Endometriosis Linked to Elevated Risk of Heart Attack, Stroke in Women
Newly reported from ESC 2024: Endometriosis Linked to Elevated Risk of Heart Attack, Stroke in Women Women with endometriosis have an approximately 20% greater risk of significant cardiac outcomes, including acute myocardial infarction and ischemic stroke, compared with women without endometriosis, according to new data presented at the European Society of Cardiology (ESC) Congress 2024. The study […]
Reporting from ESC 2024: Catching Up on Sleep on Weekends Links to 20% Lower Risk of Developing Heart Disease
Reporting from ESC 2024: Catching Up on Sleep on Weekends Links to 20% Lower Risk of Developing Heart Disease A recent study revealed people who had the most catch-up sleep on the weekends had a 20% lower risk of developing heart disease compared with those with the least weekend catch-up sleep. “The association becomes even more pronounced among individuals […]
News Coverage from ESC 2024: Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM
News Coverage from ESC 2024: Vutrisiran Reduces Cardiovascular Risk, Improves Quality of Life in ATTR-CM The HELIOS-B trial has returned promising results, indicating use of vutrisiran (Amvuttra), a novel RNA interference therapy, could provide significant benefit on both outcomes and quality of life for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Presented at the European Society of Cardiology […]
Broadcasting from ESC 2024 – ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI
Broadcasting from ESC 2024 – ABYSS Trial: No Difference in Outcomes Continuing or Stopping Beta-Blockers Following MI For patients with a history of myocardial infarction, continuing treatment with beta-blockers could be an unnecessary practice, according to the results of the ABYSS trial. Coming less than a year after REDUCE-AMI thrust the issue into the spotlight, the […]
